Holen Sie sich die Stockscreener-App
4.92
3.35%
-0.15
Schlusskurs vom Vortag:
$5.07
Offen:
$5.05
24-Stunden-Volumen:
124.00K
Relative Volume:
0.71
Marktkapitalisierung:
$92.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.38M
KGV:
-3.1742
EPS:
-1.55
Netto-Cashflow:
$-15.54M
1W Leistung:
-14.49%
1M Leistung:
-36.28%
6M Leistung:
-19.41%
1J Leistung:
-39.66%
1-Tages-Spanne:
$4.685
$5.1155
1-Wochen-Bereich:
$4.685
$5.73
52-Wochen-Spanne:
$4.685
$12.10
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Firmenname
Nuvectis Pharma Inc
Sektor
Branche
Telefon
360-837-7232
Adresse
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Vergleichen Sie NVCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| NVCT | 4.93 | 92.37M | 0 | -22.38M | -15.54M | -1.55 |
| VRTX | 450.91 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.43 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.12 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.93 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-07-13 | Eingeleitet | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges - Investing.com
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock By Investing.com - Investing.com Australia
Ron Bentsur Buys Handful Of Shares In Nuvectis Pharma - Simply Wall St
Insider Buying: Nuvectis Pharma Inc (NVCT) Chairman & CEO Acquires Shares - GuruFocus.com
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock - Investing.com
Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 20,000 Shares - MarketBeat
Nuvectis pharma chairman buys $98,400 in common stock By Investing.com - Investing.com UK
Nuvectis pharma chairman buys $98,400 in common stock - Investing.com
Vitalli ends work on Daewoong asset; Alector’s $50M loan - Endpoints News
Nuvectis Pharma reports data from Phase 1b study of NXP800 - Yahoo Finance
Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort - The Globe and Mail
500: Something went wrong - Investing.com Canada
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug - Yahoo Finance
NVCT stock touches 52-week low at $5.05 amid market fluctuations - Investing.com India
Nuvectis sinks after early-stage data for ovarian cancer therapy - MSN
U.S. Stock market: Nuvectis Pharma declined by 40.58% while Sow Good was down by 55.30% during mid day trading - Business Upturn
Nuvectis stock sinks on data for cancer drug (NVCT:NASDAQ) - Seeking Alpha
Nuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer Study - MarketWatch
Nuvectis Pharma Inc trading resumes - TipRanks
U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn
Nuvectis Pharma Reports Encouraging NXP800 Interim Data - GlobeNewswire
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase - The Bakersfield Californian
Nuvectis Pharma's NXP800 Shows Promise in Phase 1b Cancer Trial, New Dosing Success | NVCT Stock News - StockTitan
Trading (NVCT) With Integrated Risk Controls - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Announces Third Quarter 2024 Financial Results and Business Updates - Defense World
Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - MSN
Nuvectis Pharma's VP Michael Carson sells $22.5k in stock - Investing.com
Nuvectis Pharma's VP Michael Carson sells $22.5k in stock By Investing.com - Investing.com UK
FY2024 EPS Estimates for Nuvectis Pharma Raised by Analyst - Defense World
FY2024 EPS Estimate for Nuvectis Pharma Increased by Analyst - MarketBeat
Analysts Offer Predictions for Nuvectis Pharma Q1 Earnings - Defense World
Roth Capital Comments on Nuvectis Pharma Q1 Earnings - MarketBeat
Nuvectis Pharma Reports Improved Q3 Financials and Clinical Progress - TipRanks
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Trend Tracker for (NVCT) - Stock Traders Daily
Nuvectis Pharma's NXP900 Shows Promise in NSCLC Treatment, NXP800 Data Update Anticipated - Vancity Buzz
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - Business Wire
NVCTNuvectis Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Marshall Wace LLP Has $214,000 Stock Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times
Learn to Evaluate (NVCT) using the Charts - Stock Traders Daily
Here's Why We're Watching Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation - Yahoo Finance
(NVCT) Trading Advice - Stock Traders Daily
Industry Update: 3 Exciting Precision Oncology Players to Watch - openPR
A new trading data show Nuvalent Inc (NUVL) is showing positive returns. - SETE News
What's Going On With Nuvve Stock? - Benzinga
Rhumbline Advisers Has $3.18 Million Position in NVE Co. (NASDAQ:NVEC) - Defense World
Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvectis Pharma Inc-Aktie (NVCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO |
Nov 15 '24 |
Buy |
4.92 |
20,000 |
98,400 |
3,266,424 |
| Carson Michael J. | Vice President, Finance |
Nov 07 '24 |
Sale |
8.16 |
2,755 |
22,478 |
87,918 |
| BENTSUR RON | Chairman & CEO |
May 14 '24 |
Buy |
6.74 |
1,940 |
13,076 |
3,246,424 |
| BENTSUR RON | Chairman & CEO |
May 10 '24 |
Buy |
6.40 |
2,000 |
12,800 |
3,244,484 |
| Poradosu Enrique | Chief Science & Business Off |
May 10 '24 |
Buy |
6.29 |
500 |
3,145 |
1,504,319 |
| Shemesh Shay | Chief Dev. & Ops. Officer |
May 10 '24 |
Buy |
6.32 |
1,113 |
7,034 |
1,493,068 |
| BENTSUR RON | Chairman & CEO |
Mar 18 '24 |
Buy |
10.29 |
5,000 |
51,450 |
3,242,484 |
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):